

Attitudes and Perceptions of People Living with Hepatitis B on Participation in Clinical Trials

Investigators

- Chari Cohen, DrPH, MPH, Hepatitis B Foundation
- Yasmin Ibrahim, MD, PhD, Hepatitis B Foundation

Project Summary

In the U.S., up to 2.4 million people are living with chronic hepatitis B (CHB). Asian, Native Hawaiian or Other Pacific Islander, Black or African American communities are disproportionately affected by CHB with liver cancer rates up to 13 times higher than other racial and ethnic populations. Additionally, these populations are underrepresented in CHB clinical trials. Dr. Cohen's and Dr. Ibrahim's study aims to understand the barriers to clinical trial participation and support the development of tailored communication and outreach strategies that would increase clinical trial participation of underrepresented populations living with hepatitis B.

Populations Served: Asian, Native Hawaiian or Other Pacific Islander, and Black or African American

Goals/Aims:

1. To gain an understanding of how people living with CHB perceive clinical trials, and to assess barriers and challenges to clinical trial participation, specifically among Asian, Native Hawaiian or Other Pacific Islander, Black or African American populations.
2. To better understand patient perspectives about risk/benefit tradeoffs as related to CHB clinical trials, and patient thoughts on priority treatment outcomes.
3. To document strategies that can increase clinical trial participation among people from diverse backgrounds living with CHB, including strategies to incorporate innovative clinical trial design, and strategies to promote clinical trial participation.

Publications/Abstracts/Posters, etc.

- [Attitudes towards clinical trial participation among people living with chronic hepatitis B](#). Journal of Translational Science.